eJHaem (Nov 2023)
Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
- Ernesto Pérez‐Persona,
- Laida Cuevas Palomares,
- Ariane Unamunzaga Cilaurren,
- Xabier Gutiérrez López de Ocáriz,
- Buenaventura Buendía Ureña,
- Ana Vega González de Viñaspre,
- Begoña Benito Ibarrondo,
- María Carmen Molinillo Fernández,
- Ana Cordero Osúa,
- Beatriz Benítez Delgado,
- Juan José García Albás,
- Miguel Ángel Andrés Moralejo,
- José María Guinea de Castro
Affiliations
- Ernesto Pérez‐Persona
- Department of Haematology Complejo Hospitalario de Navarra Pamplona Spain
- Laida Cuevas Palomares
- Bioaraba (Onco‐Haematology Group) Vitoria‐Gasteiz Spain
- Ariane Unamunzaga Cilaurren
- Bioaraba (Onco‐Haematology Group) Vitoria‐Gasteiz Spain
- Xabier Gutiérrez López de Ocáriz
- Bioaraba (Onco‐Haematology Group) Vitoria‐Gasteiz Spain
- Buenaventura Buendía Ureña
- Bioaraba (Onco‐Haematology Group) Vitoria‐Gasteiz Spain
- Ana Vega González de Viñaspre
- Bioaraba (Onco‐Haematology Group) Vitoria‐Gasteiz Spain
- Begoña Benito Ibarrondo
- Osakidetza (OSI Araba) Hospital Universitario de Álava (Day‐care Unit) Vitoria‐Gasteiz Spain
- María Carmen Molinillo Fernández
- Osakidetza (OSI Araba) Hospital Universitario de Álava (Day‐care Unit) Vitoria‐Gasteiz Spain
- Ana Cordero Osúa
- Osakidetza (OSI Araba) Hospital Universitario de Álava (Day‐care Unit) Vitoria‐Gasteiz Spain
- Beatriz Benítez Delgado
- Osakidetza (OSI Araba) Hospital Universitario de Álava (Day‐care Unit) Vitoria‐Gasteiz Spain
- Juan José García Albás
- Osakidetza (OSI Araba) Hospital Universitario de Álava (Department of Pharmacy) Vitoria‐Gasteiz Spain
- Miguel Ángel Andrés Moralejo
- Osakidetza (OSI Araba) Hospital Universitario de Álava (Department of Pharmacy) Vitoria‐Gasteiz Spain
- José María Guinea de Castro
- Bioaraba (Onco‐Haematology Group) Vitoria‐Gasteiz Spain
- DOI
- https://doi.org/10.1002/jha2.812
- Journal volume & issue
-
Vol. 4,
no. 4
pp. 1196 – 1199
Abstract
Abstract In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day‐care hospital stays.
Keywords
